Findings

What do systematic reviews say?

1 questions · 1 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 1 · 100%

Serious adverse events · people with asthma

Benralizumab subcutaneous (SC) leads to lower serious adverse events compared with placebo (high certainty).

1 finding from 1 review

Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
Risk ratio 0.76 [0.62, 0.93]
5 studies · 3304 participants
High